Limited Access to Radioligand Therapy in Rural Areas

Because not everyone can easily travel, there’s a concern that rural or underserved patients might experience delays in getting radioligand therapy or might not get it at all. This is a health care equity issue. Some regions are exploring mobile nuclear medicine units or partnerships to deliver and administer doses at smaller hospitals occasionally, reducing the travel burden.

Radioligand therapy requires specialized equipment and experts, which are typically found in larger hospitals or cancer centers. In rural areas, there may be few or no facilities that can provide treatments like Lutetium-177 therapy. Patients living far from cities often have to travel to urban hospitals to get this care. Traveling long distances can be time-consuming and difficult. It may involve hours of driving or flights. This can be hard on patients who are already ill, and it can be costly as well. Families in rural communities sometimes have to take time off work and arrange lodging to accommodate treatment schedules. Because not everyone can easily travel, there’s a concern that rural or underserved patients might experience delays in getting radioligand therapy or might not get it at all. This is a health care equity issue. Everyone should have a fair chance at the best treatments, no matter where they live. Some regions are exploring mobile nuclear medicine units or partnerships so that doses can be delivered and administered at smaller hospitals occasionally, reducing the travel burden. Malecare encourages patients in rural areas to speak up to their hospitals and to the radioligand manufacturers to provide more equitable access to these therapies.